WAM
VRPX

Warberg Asset Management’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Warberg Asset Management’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-800
Closed -$10.3K – 268
2024
Q2 		$10.3K Buy
+800
New +$39.1K ﹤0.01% 176
2023
Q2 		– Sell
-68
Closed -$13.4K – 288
2023
Q1 		$13.4K Hold
68
– – ﹤0.01% 183
2022
Q4 		$10.6K Sell
68
-8
-11% -$1.82K ﹤0.01% 204
2022
Q3 		$23K Sell
76
-2
-3% -$720 ﹤0.01% 198
2022
Q2 		$33K Buy
78
+7
+10% +$2.87K 0.01% 166
2022
Q1 		$39K Buy
+71
New +$41.4K 0.01% 169

Other funds holding VRPX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SRCM
Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Warberg Asset Management's VRPX Position: Q3 2024 in Review

Warberg Asset Management sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q3 2024, closing a stake of 800 shares — an estimated $10.3K sold.

Warberg Asset Management first reported a position in VRPX in Q1 2022 and held it in 6 quarters. The position peaked at $39K in Q1 2022. 8 funds tracked by Wall St. Rank hold VRPX as of Q3 2024.

  • Warberg Asset Management reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Warberg Asset Management sold 800 Virpax Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $10.3K.
  • Warberg Asset Management first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
  • Warberg Asset Management's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $39K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Warberg Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.